Electronic Training of Elderly Depression With Cognitive Impairment

Not Applicable

Completed

• Conditions: Geriatric Depression; Cognitive Impairment
• Interventions: Drug: Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）

• Registration Number: NCT05588102
• Lead Sponsor: Capital Medical University

Brief Summary

late-life depression (LLD) is the most common mental illness in the elderly. Due to the increasing prevalence of population aging, it has become one of the important factors affecting the quality of life of the elderly. 50-70% of elderly patients with depression are accompanied by different degrees of cognitive impairment.

Detailed Description

Elderly patients with depression with cognitive impairment have a greater risk of dementia conversion, a worse prognosis and a higher recurrence rate. Therefore, it is urgent to provide evidence-based early intervention strategies for geriatric depression with cognitive impairment. At present, domestic and foreign guidelines do not provide clear and effective treatment plans for elderly patients with depression with cognitive impairment, and clinical research and practice also lack evidence-based treatment methods. Selective Serotonin Reuptake Inhibitors (SSRIs), the most commonly used antidepressants, do not significantly improve the cognitive impairment of elderly patients with depression, and may even aggravate the cognitive impairment of elderly patients with depression. The overall efficacy and tolerability of drug therapy in elderly patients with depression and cognitive impairment are poor. Studies have confirmed that Cognitive training can significantly improve the overall Cognitive function and multiple Cognitive domains of healthy elderly people, patients with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD). Previous studies have also preliminarily confirmed the cognitive improvement effect of cognitive training on elderly patients with depression, which provides a new idea for clinical diagnosis and treatment. Therefore, based on the urgent clinical needs and preliminary work, the development and clinical validation of a set of standardized cognitive training methods suitable for elderly patients with depression and cognitive impairment will be conducive to improve the overall efficacy of elderly patients with depression, improve the prognosis of patients, and save health resources.

Study Timeline

• Study Start: 2021-05-18
• Study First Submitted: 2022-08-17
• Study First Submitted QC: 2022-10-18
• Study First Posted: 2022-10-20
• Primary Completion: 2023-05-01
• Study Completion: 2023-08-01
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-15
• Last Update Posted: 2024-07-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 128

Inclusion Criteria

1. The patients and their family members signed the written informed consent
2. Age ≥60 years old
3. Meet the diagnostic criteria for single or recurrent major depressive disorder in the diagnostic and Statistical Manual of mental disorders Fourth Edition (DSM-V)
4. Currently in the acute phase, HAMD-17 total score at baseline ≥ 18 points
5. There are symptoms of cognitive impairment, Montreal Cognitive Assessment scale (Montreal Cognitive Assessment scale, MoCA) <26 points
6. Education level above primary school.

Exclusion Criteria

1. Patients with history of epilepsy or coronary heart disease or other serious unstable physical diseases
2. Participated in another intervention clinical study in the past 1 month
3. The following mental diseases have been or are currently diagnosed by DSM-V: organic mental disorder, Alzheimer's disease, secondary dementia caused by other causes, schizophrenia, schizophrenic affective disorder, bipolar disorder, delusional disorder, undefined mental disease, patients with drug abuse history, including alcohol and active drug abuse in the past 12 months, except nicotine
4. He has been taking antidepressants, mental retardants and other psychiatric drugs for the past 2 weeks
5. Severe aphasia, visual and hearing impairment, etc. unable to complete the scale evaluation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Selective Serotonin Reuptake Inhibitor（SSRIs）combined with Electronic cognitive training	Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）	SSRIs（Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）combined with Electronic cognitive training (60min, once a day)
SSRIs antidepressants combined with blank control Electronic training for 52 weeks	Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）	SSRIs drug treatment （Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）combined with the blank control Electronic training(subjects were allowed to use electronic products to browse the web and watch the news for 1 hours every day)

Primary Outcome Measures

Name	Time	Method
At the end of the 12th week of treatment, the change value of ADAS-Cog score of subjects in the two groups compared with baseline	12 week	The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) was developed in the 1980s to assess the level of cognitive dysfunction in Alzheimer's disease.The score of the scale is about 0-75 points, and the higher the score, the cognitive function decreases significantly

Secondary Outcome Measures

Name	Time	Method
At each follow-up point, the change value of HAMD-17 scale score of subjects in the two groups compared with baseline;	52week	17-Item Hamilton Rating Scale for Depression (HAMD-17)， Mild depression: HAMD-17 scores \> 7 points, ≤ 17 points; Moderate depression: HAMD 17 scores \> 17 points, ≤ 24 points;Severe depression: HAMD 17 scores \> 24 points.
At each follow-up point, the change value of HAMA scale score of subjects in the two groups compared with baseline;	52week	Hamilton Anxiety Scale (HAMA) is used to assess the anxiety level of patients. The 14 item cutoff value of HAMA is 14 points. The higher the score, the more serious the anxiety level.
At each follow-up point, the change value of ADAS cog scale score of subjects in the two groups compared with baseline;	52week	The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) was developed in the 1980s to assess the level of cognitive dysfunction in Alzheimer's disease.The score of the scale is about 0-75 points, and the higher the score, the cognitive function decreases significantly.

Trial Locations

Locations (1)

Beijing Anding Hospital Affiliated to Capital Medical University; 🇨🇳 Beijing, China